Global Multidrug Resistant Bacteria Market, By Diseases (Urinary Tract Infection, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, Acute Bacterial Skin and Skin Structure Infections, Hospital Acquired Bacterial Pneumonia, Acquired Bacterial Pneumonia, Others), Pathogen (E. coli, P. Aeruginosa, K. Pneumoniae, Others), Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination Therapies, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
In recent years, the multidrug resistant bacteria market is anticipated to grow rapidly during the forecast period. As per the Centers for Disease Control and Prevention (CDC), around 1.7 million illnesses and 99,000 related fatalities occur each year in American hospitals, according to the CDC. Additionally, the infection disease rate is expected to develop due to an increase in demand for point-of-care testing. In the future years, these factors are projected to influence the growth of the worldwide multidrug resistant bacteria market.
Data Bridge Market Research analyses that the multidrug resistant bacteria market was valued at USD 10.359 billion in 2021 and is expected to reach USD 16.02 billion by 2029, registering a CAGR of 5.60% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Every now and then, a new strain of bacteria is discovered that has developed a high level of resistance to antibiotics. Multidrug resistant bacteria, also known as superbugs, are microorganisms that have developed resistance to multiple drugs or antibiotics used to treat infectious diseases.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Diseases (Urinary Tract Infection, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, Acute Bacterial Skin and Skin Structure Infections, Hospital Acquired Bacterial Pneumonia, Acquired Bacterial Pneumonia, Others), Pathogen (E. coli, P. Aeruginosa, K. Pneumoniae, Others), Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination Therapies, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Merck & Co., Inc. (US), AbbVie Inc. (US), Allergan (Ireland), Melinta Therapeutics LLC (US), Achaogen, Inc (US), Nabriva Therapeutics plc (Ireland), BioVersys AG (Switzerland), Destiny Pharma plc (UK), Armata Pharmaceuticals, Inc (US), Westway Health (Ireland), NEMESIS BIOSCIENCE LTD (UK), Tetraphase Pharmaceuticals (US), Vertex Pharmaceuticals Incorporated (US)
|
|
Market Opportunities
|
|
Multidrug Resistant Bacteria Market Dynamics
Drivers
- Rise in the incidences of infectious diseases
The rising incidences of infectious diseases is a major factor driving the multidrug resistant bacteria market's growth rate. The rising number of prescriptions for infectious illness diagnostic tests can be traced back to the diagnosis and management of such disorders.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of multidrug resistant bacteria market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the multidrug resistant bacteria market. Additionally, high disposable income and sedentary lifestyle of people will result in the expansion of multidrug resistant bacteria market. Along with this, rising geriatric population and surge in cases of antibiotic-resistant infections will enhance the growth rate of the market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the multidrug resistant bacteria market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the multidrug resistant bacteria market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the drug development and distribution will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies will challenge the multidrug resistant bacteria market. Additionally, the dearth of skilled professionals and impact of COVID-19 outbreak on supply chain will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This multidrug resistant bacteria market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the multidrug resistant bacteria market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Multidrug resistant bacteria market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Multidrug Resistant Bacteria Market
Over the projected period, the multidrug resistant bacteria market is expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in a number of nations have imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world are having difficulty continuing their supply chain activities. The multidrug resistant bacteria market has also been hampered by the supply chain slowness.
Global Multidrug Resistant Bacteria Market Scope
The multidrug resistant bacteria market is segmented on the basis of diseases, pathogens, drug class, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diseases
- Urinary Tract Infection
- Intra-Abdominal Infections
- Blood Stream Infections
- Clostridium Difficile Infections
- Acute Bacterial Skin and Skin Structure Infections
- Hospital Acquired Bacterial Pneumonia
- Acquired Bacterial Pneumonia
- Others
Pathogen
- E. coli
- P. Aeruginosa
- K. Pneumoniae
- Others
Drug Class
- Oxazolidinones
- Lipoglycopeptides
- Tetracyclines
- Cephalosporins
- Combination Therapies
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Multidrug Resistant Bacteria Market Regional Analysis/Insights
The Multidrug resistant bacteria market is analysed and market size insights and trends are provided by country, diseases, pathogens, drug class, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Multidrug resistant bacteria market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the multidrug resistant bacteria market because of the introduction of newer drugs in this region. Additionally, growing presence of major key players and well-established healthcare infrastructure will further propel the market’s growth rate in this region.
Asia-Pacific are expected to grow during the forecast period due to surging number of population and rising government initiatives in this region. Also, development of healthcare infrastructure will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Multidrug Resistant Bacteria Market Share Analysis
The Multidrug resistant bacteria market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to multidrug resistant bacteria market.
Some of the major players operating in the multidrug resistant bacteria market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Sanofi (France)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
- Merck & Co., Inc. (US)
- AbbVie Inc. (US)
- Allergan (Ireland)
- Melinta Therapeutics LLC (US)
- Achaogen, Inc (US)
- Nabriva Therapeutics plc (Ireland)
- BioVersys AG (Switzerland)
- Destiny Pharma plc (UK)
- Armata Pharmaceuticals, Inc (US)
- Westway Health (Ireland)
- NEMESIS BIOSCIENCE LTD (UK)
- Tetraphase Pharmaceuticals (US)
- Vertex Pharmaceuticals Incorporated (US)
SKU-